Company intelligence / Profile preview

EndObetes

New York, New York, United States

Ownership: Private
Employees: ~3
Development stage: Other

Overview

EndObetes is a private medical device company developing minimally invasive endoscopic devices for obesity and type 2 diabetes mellitus. Its lead product, EndoBypass, is designed to mimic key anatomical and physiological effects of gastric bypass surgery by shunting food from the esophagus to the small intestine while avoiding open surgery. The company is also developing anchoring technology intended to stabilize GI endoscopic bypass devices and reduce migration risk. Based on available public information, EndObetes appears to be an early-stage medtech company advancing animal-model validation and preparing for first-in-human development rather than a clinical-stage biotech or pharmaceutical developer.

Therapeutic areas: Endocrinology
Modalities: Device
Industry: Therapeutic Medical Devices

Beyond the preview

Go deeper on EndObetes.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EndObetes.

Explore the full profile